sb 203580 has been researched along with beta-naphthoflavone in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (beta-naphthoflavone) | Trials (beta-naphthoflavone) | Recent Studies (post-2010) (beta-naphthoflavone) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 1,238 | 0 | 147 |
| Protein | Taxonomy | sb 203580 (IC50) | beta-naphthoflavone (IC50) |
|---|---|---|---|
| Cytochrome P450 1A1 | Homo sapiens (human) | 0.054 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.2767 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 2.5149 | |
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | 5.4667 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 7.185 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fahl, WE; Kong, AN; Lei, W; Mandlekar, S; Tan, TH; Yu, R | 1 |
1 other study(ies) available for sb 203580 and beta-naphthoflavone
| Article | Year |
|---|---|
p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens.
Topics: Animals; Antioxidants; beta-Naphthoflavone; Butylated Hydroxyanisole; Carcinogens; Enzyme Activation; Enzyme Induction; Gene Expression Regulation, Enzymologic; Genes, Reporter; Humans; Hydroquinones; Imidazoles; Inactivation, Metabolic; Isothiocyanates; Kinetics; MAP Kinase Kinase 3; Mice; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; NAD(P)H Dehydrogenase (Quinone); p38 Mitogen-Activated Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Sulfoxides; Thiocyanates; Tumor Cells, Cultured | 2000 |